Protease Inhibitors

"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Descriptor ID	D011480
MeSH Number(s)	D27.505.519.389.745
Concept/Terms	Protease Inhibitors Protease Inhibitors Inhibitors, Protease Endopeptidase Inhibitors Inhibitors, Endopeptidase Protease Inhibitor Inhibitor, Protease Peptide Hydrolase Inhibitors Hydrolase Inhibitors, Peptide Inhibitors, Peptide Hydrolase Peptide Peptidohydrolase Inhibitors Inhibitors, Peptide Peptidohydrolase Peptidohydrolase Inhibitors, Peptide Protease Antagonists Antagonists, Protease Antiproteases Peptidase Inhibitors Inhibitors, Peptidase

Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]

Below are MeSH descriptors whose meaning is related to "Protease Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.

Bar chart showing 54 publications over 25 distinct years, with a maximum of 5 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	1	1
1994	0	1	1
1995	0	1	1
1996	0	1	1
1997	1	1	2
1998	0	1	1
1999	1	0	1
2000	0	3	3
2001	1	2	3
2002	0	1	1
2003	2	1	3
2004	1	1	2
2005	0	5	5
2006	1	3	4
2007	0	3	3
2008	1	2	3
2009	1	1	2
2010	1	1	2
2011	0	2	2
2013	1	1	2
2014	0	2	2
2015	1	1	2
2016	3	1	4
2018	0	1	1
2020	2	0	2

Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.

Rut W, Lv Z, Zmudzinski M, Patchett S, Nayak D, Snipas SJ, El Oualid F, Huang TT, Bekes M, Drag M, Olsen SK. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Sci Adv. 2020 10; 6(42).

View in: PubMed
Zern EK, Cheng S, Wolfson AM, Hamilton MA, Zile MR, Solomon SD, Kittleson MM. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. Circ Heart Fail. 2020 02; 13(2):e006696.

View in: PubMed
Mallia-Milanes B, Dufour A, Philp C, Solis N, Klein T, Fischer M, Bolton CE, Shapiro S, Overall CM, Johnson SR. TAILS proteomics reveals dynamic changes in airway proteolysis controlling protease activity and innate immunity during COPD exacerbations. Am J Physiol Lung Cell Mol Physiol. 2018 12 01; 315(6):L1003-L1014.

View in: PubMed
Nadruz W, Claggett BL, McMurray JJ, Packer M, Zile MR, Rouleau JL, Desai AS, Swedberg K, Lefkowitz M, Shi VC, Prescott MF, Solomon SD. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.

View in: PubMed
Tew KD. Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents". Cancer Res. 2016 09 01; 76(17):4916-7.

View in: PubMed
Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.

View in: PubMed
Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.

View in: PubMed
Isonishi A, Bennett CL, Plaimauer B, Scheiflinger F, Matsumoto M, Fujimura Y. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015 Oct; 55(10):2321-30.

View in: PubMed
Singh VK, Moran RA, Afghani E, de-Madaria E. Treating acute pancreatitis: what's new? Expert Rev Gastroenterol Hepatol. 2015 Jul; 9(7):901-11.

View in: PubMed
Keum JS, Jaffa MA, Luttrell LM, Jaffa AA. Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator. J Biol Regul Homeost Agents. 2014 Oct-Dec; 28(4):587-603.

View in: PubMed

People

Explore

Similar Concepts

Top Journals